Compare Gilead Sciences, Inc. (GILD) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares Global Clean Energy ETF — how do they compare? Gilead Sciences, Inc. trades at $133.51 (market cap $163.51B), while iShares Global Clean Energy ETF trades at $18.44. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals.
| GILD | ICLN | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $23.75 |
52-Week Low | $108.22 | $13.41 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
ICLN is trading at $18.65, down 2.2% today amid bearish technical signals with 14 sell indicators versus 4 buy signals. The ETF has shown strong performance in 2026 with a 29% YTD return, outperforming the S&P 500, driven by AI momentum and high global energy prices. Recent news highlights clean energy sector strength with multiple ETF comparisons showing ICLN's competitive positioning against traditional energy and infrastructure funds.
The outlook remains cautiously optimistic as clean energy benefits from structural tailwinds including data center demand and global energy security concerns. Key risks include regulatory uncertainty from stalled US permits threatening $121 billion in investment and geopolitical tensions affecting Chinese solar manufacturers. Analyst sentiment appears mixed with some viewing the recent pullback as a buying opportunity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
